- Amarin Corporation plc is a global pharmaceutical company focused internationally on commercializing its sole therapeutic, Vascepa.
- Amarin's sole product is Vascepa, an icosapent ethyl-based cardiovascular therapeutic approved by the FDA, EMA, and various other government agencies around the globe for use in P-CVR.
- Amarin's drug, Vascepa, presents analyst-expected sales potential by 2025 of ~1.08B growing to between $1.39B-$5.38B by 2030 driven by expansion into the EU in 2021 and thereafter into China+ROW.
- Amarin is trading at a discount after the June 2021 Supreme Court rejection to revive Vascepa's US patents, but this isn't too worrisome due to the drug's cost-effective pricing.
- In summary, the author projects Amarin Corporation plc as a "buy" at a 3-4 year price target of $10 (+150% upside).
For further details see:
Amarin: Is It A Buy, Sell, Or Hold? Buy For New Global Expansion